← Eichor
Condition: Lung Adenocarcinoma Stage I Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Lung Adenocarcinoma Stage I

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Phase 1 · 29 location(s) · Novartis Pharmaceuticals · NCT06562192Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors
Phase 1 · 1 location(s) · Novartis Pharmaceuticals · NCT07630961Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followe
Phase 1/Phase 2 · 1 location(s) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd · NCT06440057GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
Phase 1 · 2 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT03198546Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Phase 1/Phase 2 · 2 location(s) · University of Arizona · NCT06814496Improving the Intraoperative Diagnosis Accuracy of Invasiveness for Small-sized Lung Adenocarcinoma
Phase N/A · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT05830812MOv19-BBz CAR T Cells in FRa+ Cancers
Phase 1 · 1 location(s) · University of Pennsylvania · NCT07116057A Phase I Study of HS-20108 in Participants With Advanced Solid Tumors
Phase 1 · 1 location(s) · Hansoh BioMedical R&D Company · NCT06936735A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Phase 1/Phase 2 · 14 location(s) · Volastra Therapeutics, Inc. · NCT05902988A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patien
Phase 1/Phase 2 · 1 location(s) · Shenzhen Ionova Life Sciences Co., Ltd. · NCT07610798Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)
Phase 2 · 2 location(s) · Samsung Medical Center · NCT04591002Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Phase 1/Phase 2 · 66 location(s) · Genmab · NCT05579366A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
Phase 1 · 17 location(s) · NextCure, Inc. · NCT06792552Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma
EARLY_Phase 1 · 1 location(s) · Jonsson Comprehensive Cancer Center · NCT07235280Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Phase 1/Phase 2 · 60 location(s) · AstraZeneca · NCT05797168Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followe
Phase 1/Phase 2 · 1 location(s) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd · NCT06283719Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma
Phase 2 · 1 location(s) · Samsung Medical Center · NCT05528458JMT106 Injection in the Treatment of Advanced Solid Tumors
Phase 1 · 1 location(s) · Shanghai JMT-Bio Inc. · NCT07275073XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.
Phase 1/Phase 2 · 1 location(s) · Evopoint Biosciences Inc. · NCT06792435A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
Phase 1 · 1 location(s) · GONGCHU Biotechnology Co., Ltd · NCT06508307Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%
Phase 2 · 1 location(s) · Shanghai Pulmonary Hospital, Shanghai, China · NCT03351842MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Phase 1 · 2 location(s) · Memgen, Inc. · NCT05076760Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer
Phase 1/Phase 2 · 2 location(s) · Dana-Farber Cancer Institute · NCT04789486A Phase I Study of [68Ga]Ga-DWJ155 in Patients With Breast and Lung Cancers
Phase 1 · 1 location(s) · Novartis Pharmaceuticals · NCT07117214TCR1188-ABC Cells in KRAS-mutated Cancers
Phase 1 · 1 location(s) · University of Pennsylvania · NCT07594067A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multi
Phase 1 · 69 location(s) · Shanghai Henlius Biotech · NCT07160335Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma
Phase 2 · 1 location(s) · Shanghai Pulmonary Hospital, Shanghai, China · NCT06528847A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 13 location(s) · AstraZeneca · NCT07115043A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06066138A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Phase 1/Phase 2 · 6 location(s) · Tanabe Pharma America, Inc. · NCT06943521
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.